Biologic therapies specifically targeting tumour necrosis factor-alpha (TNF-α) are a recognised, independent risk factor for TB disease due to the central role of TNF-α in granuloma formation and maintenance [6, 10]. The gene discussed is TNF; the disease is tuberculosis.